PTEN inhibitors Myriad Details Companion Dx Strategy for PARP, PTEN Inhibitors at Goldman Sachs Conference Premium "Myriad is very much a player in the field of companion diagnostics," Myriad Genetics CEO Peter Meldrum told investors at the Goldman Sachs annual global healthcare conference earlier this month. Breaking News Court Grants Natera Injunction Against Invitae, ArcherDx in Use of Patented Products People in the News at Vizgen, BioSkryb Genomics, Deepcell, CellChorus, More Germline Mutagenesis Traced Back to Meiotic Breaks, Error-Prone Repair New Products Posted to GenomeWeb: Active Motif, Golden Helix, Variantyx White Adipose Tissue Proteins Linked to Diabetes, Exercise Training in Proteomics Study
